Search results
Your search for process/pmg6 returned no results
Showing 2761 to 2775 of 2854 results for process
Showing 2761 to 2775 of 2854 results for process
Bed frames for adults in acute medical or surgical hospital wards: late-stage assessment (HTG759)
Late stage assessment (LSA) guidance on bed frames for adults in acute medical or surgical hospital wards.
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) and chemotherapy for untreated metastatic non-small-cell lung cancer.
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for relapsed or refractory follicular lymphoma in adults.
This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
How a collaborative taskforce is helping increase the uptake of biosimilars within the health and care sector.
This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women and pregnant people to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.
View recommendations for NG235Show all sections
Sections for NG235
- Overview
- Recommendations
- Recommendations for research
- Rationale and impact
- Context
- Appendix A: Adverse outcomes for different places of birth
- Appendix B: Outcomes for different places of birth – by BMI at booking
- Appendix C: Outcomes for intravenous remifentanil patient-controlled analgesia (PCA) compared with intramuscular pethidine
This guideline covers diagnosing and managing epilepsy in children, young people and adults in primary and secondary care, and referral to tertiary services. It aims to improve diagnosis and treatment for different seizure types and epilepsy syndromes, and reduce the risks for people with epilepsy.
Show all sections
Sections for NG217
- Overview
- 1 Diagnosis and assessment of epilepsy
- 2 Information and support
- 3 Referral to tertiary specialist services
- 4 Principles of treatment, safety, monitoring and withdrawal
- 5 Treating epileptic seizures in children, young people and adults
- 6 Treating childhood-onset epilepsies
- 7 Treating status epilepticus, repeated or cluster seizures, and prolonged seizures
First treatment for vitiligo recommended by NICE for NHS use, bringing hope to over 80,000 people
For the first time, NICE has recommended a medicine that effectively treats the underlying cause of devastating skin condition vitiligo
Online help programme recommended for people with eating disorders
An online therapy programme can be used to help people aged 16 and over with eating disorders whilst they wait for specialist NHS treatment, an independent NICE has said.
Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars
More than 7,000 people in England will now be able to access to a life-extending treatment for advanced bowel cancer.
NICE's prioritisation process explained – what healthtech developers need to know
Understand why we're prioritising key topic areas for evaluation and what it means for innovators
Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.
Our associate director of NICE Advice outlines his top tips for healthtech companies, helping them chart a clear path from innovation to NHS adoption.
New AI tools could help save lives by spotting warning signs of bowel cancer earlier
Five smart technologies that act as a "second pair of eyes" during bowel examinations have been conditionally recommended by NICE for NHS use, potentially helping doctors spot harmful growths that could turn into cancer.
For more than 25 years NICE has helped practitioners and commissioners get the best care to people, fast, while ensuring value for the taxpayer.